Fortbildungen / Formations continues 2012 - IUMSP

kontrollierten Screening-Studien eingeschlossen werden
[16]. Nach unserem Wissen fehlt leider momentan in der
Schweiz eine solche Studie, weshalb wir die Pneumologischen
und Onkologischen Fachgesellschaften und Ligen
aufrufen möchten, gemeinsam eine solche zu entwickeln.
Referenzen
1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA
Cancer J Clin 2011;61:69.
2. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest
2003;123:21S.
3. Zang EA, Wynder EL. Differences in lung cancer risk between
men and women: examination of the evidence. J Natl Cancer Inst
1996;88:183.
4. Peto R, Darby.S, Deo H, Silcocks P, Whitley E, Doll R. Smoking,
smoking cessation, and lung cancer in the UK since 1950: combination
of national statistics with two case -control studies. BMJ 2000; 321:323-9.
5. Detterbeck FC, Boffa DJ, Tanoue LT. The New Lung Cancer Staging
System. Chest 2009;136:260-71.
6. Flieder DB, Port JL, Korst RJ, et al. Tumor size is a determinant
of stage distribution in t1 non-small cell lung cancer. Chest
2005;128:2304.
7. Marcus PM, Bergstralh EJ, Fagerstrom RM et al. Lung cancer
mortality in the Mayo Lung Project: impact of extended follow-up. J
Natl Cancer Inst 2000; 92(16):1308-16.
8. Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP,
Fontana RS. Extended lung cancer incidence follow-up in the Mayo
Lung Project and overdiagnosis. J Natl Cancer Inst 2006; 98(11):748-56.
9. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with
sputum cytologic examination, chest radiography, and computed
tomography: an update for the U.S. Preventive Services Task Force.
Ann Intern Med 2004;140:740-53.
10. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients
with stage I lung cancer detected on CT screening. N Engl J Med
2006;355:1763.
11. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based
selection from the general population in a screening trial: selection
criteria, recruitment and power for the Dutch-Belgian randomised
LUNGENKREBS
lung cancer multi-slice CT screening trial (NELSON). Int J Cancer
2007; 120:868.
12. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management
of lung nodules detected by volume CT scanning. N Engl J Med
2009;361:2221.
13. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer
mortality with low-dose computed tomographic screening. N Engl J
Med 2011;365:395-409.
14. Wisnivesky JP, Mushlin A, Sicherman N, Henschke CI. Costeffectiveness
of lowdose CT screening for lung cancer: preliminary
results of baseline screening. Chest 2003;124:614-21.
15. Mc Mahon PM, Kong CY, Bouzon C et al. Cost-Effectiveness of
Computed Tomography Screening for Lung Cancer in the United
States. J Thorac Oncol 2011; 6:1841-8.
16. Field J, Boffetta P, Dresler C et al. IASLC’s 2011 statement on
ct screening for lung cancer. Available from: http:// iaslc.org/policies/
statement-on-ct-screening/
17. Wood DE, Eapen GA, Ettinger DS et al. NCCN clinical practice
guidelines in oncology (NCCN Guidelines®). Lung cancer screening
Version I.2012. Available from: http://www.nccn.org/professionals/
physician_gls/recently_updated.asp
18. Crinò L, Weder W, van Meerbeeck J, Felip E. Early stage and
locally advanced (non-metastatic) non-small-cell lung cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol 2010;21:103-15.
19. Tallent A. ASCO statement on publication of the national lung
screening trial results. Available from: http://www.asco.org/ASCOv2/
Press+Center/Latest+News+Releases/ASCO+Statement+on+Publication
+of+the+ National+Lung+Screening+Trial+Results
20. Unger M. A Pause, Progress, and Reassessment in Lung Cancer
Screening. NEJM 2006;355:1822-4.
Korrespondenz:
PD Dr. med. Oliver Gautschi
Leitender Arzt
Medizinische Onkologie
Luzerner Kantonsspital
CH-6000 Luzern
oliver.gautschi@luks.ch
Schweizer Krebsbulletin � Nr. 2/2012 109